静脉美托洛尔与地尔硫䓬治疗伴心力衰竭的心房颤动
该回顾性研究纳入2018年1月1日至2021年7月31日急诊中心就诊的伴心力衰竭的房颤快速心室率患者193例(地尔硫䓬134例 vs 美托洛尔59例),平均EF 48.2±14.2%,30%为射血分数降低的心衰、64%为射血分数保留的心衰。主要终点静脉推注后30分钟心率<100次/分的达标率两组无显著差异(地尔硫䓬55% vs 美托洛尔41%,p=0.063)。地尔硫䓬控制心率更快(13[9,125] min vs 27[5,50] min,p=0.009),30分钟和60分钟心率降幅更大,30分钟、60分钟及离院/转出时心率降幅≥20%的比例更高。安全结局无差异,作者认为需进一步研究地尔硫䓬在伴心衰房颤患者中的安全性。
要点
- 主要终点30分钟心率<100次/分的达标率地尔硫䓬55% vs 美托洛尔41%,p=0.063,未达统计学显著。
- 地尔硫䓬控制心率更快:13[9,125] min vs 美托洛尔27[5,50] min,p=0.009。
- 30分钟心率降幅地尔硫䓬33.2±25.4次/分 vs 美托洛尔19.7±19.7次/分,p<0.001;60分钟31±23.5次/分 vs 19.6±19.1次/分,p=0.002。
- 心率降幅≥20%的比例地尔硫䓬在30分钟(63% vs 27%,p<0.001)、60分钟(59% vs 41%,p=0.019)及离院/转出时(70% vs 49%,p=0.005)均更高。
- 安全结局(心动过缓、低血压、气短、氧需求增加、EF变化、急性肾损伤或肾脏替代治疗)两组无差异。
适用人群与场景
- 2018年1月1日至2021年7月31日就诊于急诊中心、伴心力衰竭的房颤快速心室率患者,年龄≥18岁,接受静脉推注美托洛尔或地尔硫䓬,且有记录的基线射血分数。
- 共纳入193例(地尔硫䓬134例 vs 美托洛尔59例),年龄73.3±12.2岁,63%为女性;平均EF 48.2±14.2%,30%为射血分数降低的心衰,64%为射血分数保留的心衰。
诊断标准与关键阈值
- 主要有效性终点为静脉推注美托洛尔或地尔硫䓬后30分钟成功控制心率,定义为心率<100次/分。
处置流程与药物剂量
- 急诊中心静脉推注美托洛尔或地尔硫䓬用于伴心力衰竭的房颤快速心室率患者。
研究设计与关键结果
- 回顾性、经IRB批准的研究,共评估2580例,最终纳入193例(地尔硫䓬134例 vs 美托洛尔59例)。
- 主要终点:静脉推注后30分钟心率<100次/分的达标率地尔硫䓬55% vs 美托洛尔41%,p=0.063,未达统计学显著。
- 地尔硫䓬控制心率更快:13[9,125] min vs 美托洛尔27[5,50] min,p=0.009。
- 30分钟心率降幅地尔硫䓬33.2±25.4次/分 vs 美托洛尔19.7±19.7次/分,p<0.001;60分钟心率降幅地尔硫䓬31±23.5次/分 vs 美托洛尔19.6±19.1次/分,p=0.002。
- 心率降幅≥20%的比例:30分钟地尔硫䓬63% vs 美托洛尔27%,p<0.001;60分钟地尔硫䓬59% vs 美托洛尔41%,p=0.019;离院或转出时地尔硫䓬70% vs 美托洛尔49%,p=0.005。
- 安全结局(心动过缓、低血压、气短、氧需求增加、EF变化、急性肾损伤或肾脏替代治疗)两组无差异。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 作者结论指出,伴心衰的房颤快速心室率急性管理具有挑战性;虽然30分钟心率达标率地尔硫䓬与美托洛尔无显著差异,但地尔硫䓬更快降低心率且心率降幅≥20%的比例更高,安全结局无差异。
- 作者指出需进一步研究评估地尔硫䓬在伴心衰房颤患者中的安全性。
对床旁实践的改变
- 在伴心力衰竭的房颤快速心室率急诊患者中,静脉地尔硫䓬较美托洛尔能更快降低心率、更常达到≥20%的心率降幅,且本研究中安全结局无差异。
- 作者认为,伴心衰的房颤快速心室率急性管理具有挑战性,需进一步研究评估地尔硫䓬在该人群中的安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Atrial fibrillation (Afib) with rapid ventricular response (RVR) is acutely treated with intravenous push (IVP) metoprolol (MET) or diltiazem (DIL). In heart failure (HF) patients, diltiazem is not recommended due to negative inotropic effects. Studies comparing the treatment of atrial fibrillation often exclude HF. Hirschy et al. evaluated HF patients with concomitant Afib with RVR who received IVP metoprolol or diltiazem to determine their effectiveness and safety. They found similar safety and effectiveness outcomes between the two groups.
METHODS: This retrospective, IRB-approved study evaluated patients presenting to the emergency center (EC) with Afib with RVR and HF from January 1, 2018 to July 31, 2021. Included patients were 18 years of age or older, received IVP metoprolol or diltiazem in the EC, and had a recorded baseline ejection fraction (EF). The primary effectiveness outcome was successful heart rate (HR) control 30 min after treatment with either IVP metoprolol or diltiazem, which was defined as HR <100 beats per minute (bpm). Secondary effectiveness outcomes included HR control 60 min post-IVP and at EC discharge or transfer and HR reduction >20% at 30 min after IVP, 60 min after IVP, and at time of discharge or transfer. Other secondary outcomes included the time to adequate HR control, the total dose of IVP metoprolol or diltiazem given, any additional rate-controlling agents given, and crossover between metoprolol and diltiazem. Safety outcomes included bradycardia, hypotension, shortness of breath, increased oxygen requirements, change in EF, acute kidney injury or renal replacement therapy.
RESULTS: Of 2580 evaluated, 193 patients were included (134 DIL vs. 59 MET) with age 73.3 ± 12.2 years, 63% female. The average EF was 48.2 ± 14.2% and 30% of patients had heart failure with reduced ejection fraction (HFrEF) while 64% had heart failure with preserved ejection fraction (HFpEF). Effective heart rate control 30 min post-IVP was not different between the two groups (55% DIL vs. 41% MET, p = 0.063). DIL effectively controlled HR quicker than MET (13 [9, 125] DIL vs. 27 [5, 50] MET, min, p = 0.009). DIL resulted in greater HR reductions at 30 min (33.2 ± 25.4 DIL vs. 19.7 ± 19.7 MET, bpm, p < 0.001) and at 60 min (31 ± 23.5 DIL vs. 19.6 ± 19.1 MET, bpm, p = 0.002). DIL also more frequently resulted in a HR reduction of 20% or greater at 30 min (63% DIL vs. 27% MET, p < 0.001), 60 min post-IVP (59% DIL vs. 41% MET, p = 0.019), and at time of patient discharge or transfer from the EC (70% DIL vs. 49% MET, p = 0.005). No differences in safety outcomes were identified.
CONCLUSION: Acute management of patients with Afib with RVR and HF is challenging. While successful rate control at 30 min was not significantly different between diltiazem and metoprolol, IVP diltiazem reduced HR more quickly and reduced HR by 20% or greater more frequently than IVP metoprolol with no safety outcome differences. Further studies are needed to evaluate diltiazem's safety in patients with Afib and HF.
参考来源
- Compagner CT, Wysocki CR, Reich EK, et al. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. Am J Emerg Med. 2022. PMID: 36252310. doi:10.1016/j.ajem.2022.10.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。